Navigation Links
Tarix Orphan Receives FDA Fast Track Designation for TXA127 as Potential Treatment for Duchenne Muscular Dystrophy
Date:10/6/2015

CAMBRIDGE, Mass., Oct. 6, 2015 /PRNewswire/ -- Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to TXA127 (angiotensin 1-7) to reduce skeletal muscle damage and fibrosis and thereby improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients. Tarix Orphan has received notice that clinical testing under the company's Investigational New Drug (IND) application for TXA127 may proceed, and the company expects to initiate a multi-site Phase 2 safety and efficacy study in patients with DMD in early 2016 at both U.S. and European trial sites. Tarix has previously received Orphan Drug Status for TXA127 in the DMD indication in both the United States and Europe.

"Studies with TXA127 have shown significant development potential in preclinical models of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy, and congenital muscular dystrophy, MDC1A and other conditions associated with the TGF-beta pathway. This peptide has several biological actions and has shown positive effects in animals including reductions in muscle fibrosis, increases in muscle strength and ambulation in affected animals, as well as normalization of cardiac dysfunction," said Rick Franklin, Tarix Orphan Chief Executive Officer. "We look forward to beginning our multi-site international Phase 2 study in DMD patients in early 2016. We are additionally preparing a clinical protocol for a study of TXA127 in children with congenital muscular dystrophy (MDC1A), and hope to initiate studies in 2016 in that indication, for which there are no current treatments."

The planned Phase 2 trial will be a double-blind, randomized, placebo-controlled safety and efficacy study of TXA127 in 45 ambulant patients with DMD, conducted for 48 weeks, followed by a 96-week open-label extension study. The study will be conducted at 3 sites in the United States and 3 in Europe. Endpoints for the study will include assessment of muscle quality by MRI, ambulatory assessments including the 2-Minute Walk Test, and safety assessments.

About the U.S. FDA's Fast Track Designation
Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet medical needs. Companies that receive Fast Track designation are allowed to submit New Drug Applications (NDA) or Biologics License Applications (BLA) on a rolling basis, expediting the FDA review process and benefiting from more frequent communication with the agency to discuss aspects of clinical development. Additionally, drugs that receive Fast Track designation are eligible for accelerated approval and priority review.

About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a genetic disorder occurring primarily in boys that is characterized by rapidly progressive muscle degeneration and weakness. It is caused by a defective gene for dystrophin, a protein in muscle. Duchenne muscular dystrophy affects approximately 1 in 3500 male births worldwide, with symptoms usually appearing before age 6. Because DMD is an inherited disorder, risks include a family history of Duchenne muscular dystrophy. There is no cure for DMD. Current treatments are aimed at managing the symptoms and slowing the course of the disease.

About TXA127
TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide Angiotensin (1-7) which Tarix Orphan is developing for the treatment of a number of orphan and genetic diseases, with an initial focus on DMD. Additional diseases which may benefit from treatment with TXA127 include congenital muscular dystrophies, Marfan Syndrome, and amyotrophic lateral sclerosis (ALS). TXA127 is part of the "alternative renin angiotensin system (RAS)" and counteracts the "classical" RAS, which promotes hypertension, fibrosis, hypertrophy and inflammation.

About Tarix Orphan
Tarix Orphan LLC is a private biopharmaceutical company focused on the development of TXA127, a pharmaceutical formulation of the naturally occurring peptide Angiotensin (1-7), for the treatment of rare neuromuscular and connective tissue diseases. TXA127 has shown therapeutic activity in animal models of Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophy (LGMD), congenital muscular dystrophy (MDC1A), Marfan syndrome, and ALS. Tarix Orphan has broad IP protection for TXA127, and Orphan Drug Designations (ODDs) have been granted for DMD and LGMD in the United States, and for DMD in Europe. For more information on Tarix Orphan, please visit our website at http://www.tarixorphan.com/.

Contact:

Elizabeth Wagner, Vice President
Tarix Orphan
elizabeth.wagner@tarixpharma.com

For Media:

Joan Kureczka
Kureczka/Martin Associates
Joan@kureczka-martin.com
Phone: 415-821-2413

Logo - http://photos.prnewswire.com/prnh/20151005/274091LOGO


'/>"/>
SOURCE Tarix Pharmaceuticals
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Blueprint Medicines Receives FDA Orphan Drug Designation for Novel Drug Candidate for Treatment of Hepatocellular Carcinoma
2. Cloud Pharmaceuticals and THERAMetrics Form Strategic Drug Development Collaboration Targeting Orphan CNS Diseases
3. Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
4. MTG Biotherapeutics Announces that MTG-201 was Granted Orphan Drug Designation by the US FDA for the Treatment of Malignant Mesothelioma
5. Keynote Speakers Announced for NORDs Rare Diseases & Orphan Products Breakthrough Summit
6. Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
7. HSRx Group In-Licenses Portfolio of Novel Late-Stage Orphan and Breakthrough Combination Drugs, Acquires Ready-for-Market OTC Drugs
8. Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions
9. NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer
10. Trigeminal Neuralgia Represents an Attractive Orphan Opportunity in the Pain Field
11. Trigeminusneuralgie ist attraktiv für die Entwicklung eines Orphan-Arzneimittels für die Schmerztherapie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
Breaking Medicine News(10 mins):